This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Randomized Controlled Trial  • Dermatologic Procedures  • Phototherapy  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Narrowband UV-B (NB UV-B) therapy has recently been shown to be effective in the repigmentation of patients with vitiligo, without significant adverse effects. In recent uncontrolled studies, topical tacrolimus therapy has also been reported to cause repigmentation of vitiligo lesions, particularly on the face and neck. To explore the possibility of synergism between these 2 modalities, we conducted a prospective, randomized, controlled trial of therapy with NB UV-B and tacrolimus or placebo for patients with generalized vitiligo.

Methods

After local university institutional review board approval and informed consent were obtained, patients with the following inclusion criteria were recruited: generalized vitiligo (5%-50% body surface area); 2 paired vitiligo patches, at least 2 x 2 cm in greatest dimension, on each side of the body to serve as target lesions (areas classically resistant to treatment, such as the elbows, hands, knees, and feet were excluded); skin types III to VI; and stable disease . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION
Don Mehrabi, MD; Amit G. Pandya, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Vitiligo
Taieb and Picardo
NEJM 2009;360:160-169.
FULL TEXT